![](assets_2023/img/relations_bg_top.png)
Captor Therapeutics ®
News
![miniatura](https://captortherapeutics.com/userfiles/news/105-1689680670_thumb.jpg)
July 18, 2023
Captor Therapeutics with PLN 52.2 million co-funding from The Medical Research Agency of Poland
![miniatura](https://captortherapeutics.com/userfiles/news/91-1686135768_thumb.jpg)
May 29, 2023
Captor Therapeutics publishes Q1 2023 financial results
![miniatura](https://captortherapeutics.com/userfiles/news/77-1684392313_thumb.jpg)
April 07, 2023
Captor Therapeutics has published its 2022 report. The past year was a period of dynamic growth for the Company in both science and business.
![miniatura](https://captortherapeutics.com/userfiles/news/73-1684392372_thumb.jpg)
March 27, 2023
Captor Therapeutics Discloses Molecular Targets of Pipeline’s Lead Assets and Invites Stakeholders to Webcast
![miniatura](https://captortherapeutics.com/userfiles/news/69-1684392455_thumb.jpg)
March 06, 2023
Captor Therapeutics Announces Three-Year Strategic Objectives
![miniatura](https://captortherapeutics.com/userfiles/news/68-1684392461_thumb.jpg)
December 19, 2022
Captor Therapeutics senior management to hold investor and partnering meetings around J.P. Morgan 41st Annual Healthcare Conference
![miniatura](https://captortherapeutics.com/userfiles/news/67-1684392465_thumb.jpg)
November 24, 2022
Captor Therapeutics reports Q3 2022 results and provides business update. Lead assets approaching the clinic and new significant drug discovery collaboration signed with Ono Pharmaceutical
![miniatura](https://captortherapeutics.com/userfiles/news/66-1684392471_thumb.jpg)
November 14, 2022
Ono Pharmaceutical and Captor Therapeutics announce drug discovery collaboration to develop small molecule protein degraders for the treatment of neurodegenerative diseases